Show simple item record

Report from a Survey of Parents Regarding the Use of Cannabidiol (Medicinal cannabis) in Mexican Children with Refractory Epilepsy

dc.creatorCARLOS G. AGUIRRE VELAZQUEZ;501776
dc.creatorCARLOS G. AGUIRRE VELAZQUEZ;501776es
dc.date2017
dc.date.accessioned2018-10-18T19:54:17Z
dc.date.available2018-10-18T19:54:17Z
dc.identifier.issn20901852
dc.identifier.doi10.1155/2017/2985729
dc.identifier.urihttp://hdl.handle.net/11285/630274
dc.descriptionStructured online surveys were used to explore the experiences of the parents of children with refractory epilepsy using medicinal cannabis in Mexico during September 2016. The surveys, which were completed in full, were reviewed, and 53 cases of children aged between 9 months and 18 years were identified. Of these, 43 cases (82%) were from Mexico and 10 (18%) were from Latin American countries. Of the 43 Mexican cases, the diagnoses were as follows: 20 cases (47%) had Lennox-Gastaut syndrome (LGS); 13 cases (30%) had unspecified refractory epilepsy (URE); 8 cases (19%) had West syndrome (WS); 1 case (2%) had Doose syndrome (DS); and 1 case (2%) had Ohtahara syndrome (OS). In total, 47.1% of cases had previously been treated with 9 or more anticonvulsant therapies. The parents reported a decrease in convulsions when cannabidiol was used in 81.3% of the cases; a moderate to significant decrease occurred in 51% of cases, and 16% of cases were free from seizure. The number of antiepileptic drugs being used was reduced in 9/43 (20.9%) cases. No serious adverse effects were reported, with only some mild adverse effects, such as increased appetite or changes in sleep patterns, reported in 42% of cases. © 2017 Carlos G. Aguirre-Velázquez.
dc.languageeng
dc.publisherHindawi Limited
dc.relationhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85016556479&doi=10.1155%2f2017%2f2985729&partnerID=40&md5=64bdca93de25348c3d173ea866ab9324
dc.relationInvestigadores
dc.relationEstudiantes
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0
dc.sourceNeurology Research International
dc.subjectanticonvulsive agent
dc.subjectmedical cannabis
dc.subjectanticonvulsant therapy
dc.subjectArticle
dc.subjectchild
dc.subjectclinical article
dc.subjectconstipation
dc.subjectdecreased appetite
dc.subjectdiarrhea
dc.subjectdrug resistant epilepsy
dc.subjectfemale
dc.subjectflatulence
dc.subjecthealth survey
dc.subjecthuman
dc.subjectincreased appetite
dc.subjectinfantile spasm
dc.subjectinsomnia
dc.subjectLennox Gastaut syndrome
dc.subjectmale
dc.subjectMexico
dc.subjectmyoclonic astatic epilepsy
dc.subjectobservational study
dc.subjectohtahara syndrome
dc.subjectparent
dc.subjectpreschool child
dc.subjectschool child
dc.subjectsleep disorder
dc.subjectsleep pattern
dc.subjectSouth and Central America
dc.subjecttic
dc.subject.classification7 INGENIERÍA Y TECNOLOGÍA
dc.titleReport from a Survey of Parents Regarding the Use of Cannabidiol (Medicinal cannabis) in Mexican Children with Refractory Epilepsy
dc.typeArtículo
dc.identifier.volume2017
refterms.dateFOA2018-10-18T19:54:17Z


Files in this item

Thumbnail
Name:
9784075.pdf
Size:
1.423Mb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/openAccess
Except where otherwise noted, this item's license is described as info:eu-repo/semantics/openAccess